1 The FLOW trial achieved its primary endpoint with Ozempic 1 mg, demonstrating a statistically significant and superior 24% relative risk reduction of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease (4.9% absolute risk reduction at 3 years) compared to placebo, when added to standard of care
However, the relationship between GLP-1 therapy, weight loss, and bone health remains complex and context-dependent
This screening is a fundamental safety measure and should be documented in the patient's medical records
However, this adverse effect occurred less frequently than GI disturbances, and the mean cholesterol concentration in the study population was only marginally higher than baseline values
All you get with your membership Open the award-winning WW app, and open up a world of support